Capitolis Liquid Global Markets LLC reduced its stake in shares of Cigna Group (NYSE:CI - Free Report) by 84.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,892 shares of the health services provider's stock after selling 129,308 shares during the period. Capitolis Liquid Global Markets LLC's holdings in Cigna Group were worth $6,887,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of CI. Harbor Capital Advisors Inc. lifted its position in shares of Cigna Group by 119.5% during the third quarter. Harbor Capital Advisors Inc. now owns 90 shares of the health services provider's stock worth $26,000 after purchasing an additional 49 shares during the last quarter. Collier Financial acquired a new position in Cigna Group in the third quarter worth about $34,000. Founders Capital Management increased its holdings in Cigna Group by 53.0% in the third quarter. Founders Capital Management now owns 153 shares of the health services provider's stock valued at $44,000 after buying an additional 53 shares during the last quarter. Traub Capital Management LLC acquired a new stake in Cigna Group during the second quarter valued at approximately $48,000. Finally, Twin Peaks Wealth Advisors LLC acquired a new stake in Cigna Group during the second quarter valued at approximately $52,000. Institutional investors own 86.99% of the company's stock.
Insider Activity
In other Cigna Group news, insider Nicole S. Jones sold 2,307 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $288.91, for a total transaction of $666,515.37. Following the completion of the transaction, the insider directly owned 32,647 shares of the company's stock, valued at $9,432,044.77. The trade was a 6.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Everett Neville sold 1,719 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $288.91, for a total transaction of $496,636.29. Following the completion of the transaction, the insider owned 5,670 shares of the company's stock, valued at approximately $1,638,119.70. This trade represents a 23.26% decrease in their position. The SEC filing for this sale provides additional information. 0.70% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several research analysts have recently commented on the company. Wall Street Zen upgraded Cigna Group from a "hold" rating to a "buy" rating in a research report on Saturday, February 7th. Sanford C. Bernstein raised Cigna Group from a "market perform" rating to an "outperform" rating and upped their price target for the company from $307.00 to $358.00 in a research report on Thursday. Guggenheim reaffirmed a "buy" rating and issued a $318.00 price objective on shares of Cigna Group in a report on Monday, February 2nd. Zacks Research upgraded shares of Cigna Group from a "strong sell" rating to a "hold" rating in a research note on Monday, January 5th. Finally, TD Cowen increased their target price on shares of Cigna Group from $333.00 to $338.00 and gave the stock a "buy" rating in a report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Cigna Group has an average rating of "Moderate Buy" and an average target price of $333.11.
Read Our Latest Stock Analysis on CI
More Cigna Group News
Here are the key news stories impacting Cigna Group this week:
- Positive Sentiment: Sanford C. Bernstein upgraded Cigna to "outperform" and raised its price target to $358, citing PBM reform as a clearing event and improved outlook for Evernorth — a catalyst for multiple analysts to raise estimates. Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event
- Positive Sentiment: Zacks notes CI trades below the industry P/E and highlights Evernorth growth, steady earnings beats and buybacks as supports for the investment case — a valuation/earnings combo that helps explain buying interest. Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
- Neutral Sentiment: A valuation review highlights recent share-price weakness versus the specialty-pharmacy growth narrative — useful context for investors weighing whether current discounts already reflect execution risks. Evaluating Cigna Group (CI) Valuation After Recent Share Price Weakness And Specialty Pharmacy Growth Narrative
- Neutral Sentiment: A head-to-head comparison with CVS frames Cigna as the play for stronger earnings quality and capital discipline, while reminding long-term investors to consider income, stability and valuation differences when choosing exposure. CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?
- Neutral Sentiment: Zacks’ broader industry outlook continues to single out major HMOs (including Cigna) as key players in a sector balancing tech-enabled growth and policy/operational headwinds. Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Centene
- Negative Sentiment: Barclays and commentators warn that the timing of a CEO change could surprise investors and introduce strategic/operational uncertainty during a critical execution window. Management transition risk may weigh on sentiment until plans are clearer. The Cigna Group (CI) CEO Change Timing May Come As Surprise to Some Investors, According to Barclays
- Negative Sentiment: Industry pieces flag escalating medical costs, nursing shortages and margin pressure as sector-wide risks that could blunt near-term earnings leverage for HMOs, including Cigna. 4 HMO Stocks to Watch Despite Escalating Costs, Nursing Shortage
Cigna Group Trading Up 0.5%
Shares of NYSE CI opened at $267.15 on Monday. The company has a market cap of $70.40 billion, a price-to-earnings ratio of 12.04, a price-to-earnings-growth ratio of 0.93 and a beta of 0.27. Cigna Group has a 12-month low of $239.51 and a 12-month high of $350.00. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of 0.74. The stock's 50 day simple moving average is $279.60 and its 200 day simple moving average is $282.70.
Cigna Group (NYSE:CI - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The health services provider reported $8.08 EPS for the quarter, topping analysts' consensus estimates of $7.88 by $0.20. Cigna Group had a return on equity of 19.46% and a net margin of 2.17%.The firm had revenue of $72.50 billion during the quarter, compared to the consensus estimate of $69.53 billion. During the same period in the prior year, the business earned $6.64 EPS. The firm's revenue was up 10.4% on a year-over-year basis. Cigna Group has set its FY 2026 guidance at 30.250- EPS. Equities research analysts expect that Cigna Group will post 29.77 EPS for the current year.
Cigna Group Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, March 5th will be given a dividend of $1.56 per share. This is an increase from Cigna Group's previous quarterly dividend of $1.51. This represents a $6.24 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, March 5th. Cigna Group's payout ratio is currently 28.13%.
Cigna Group Profile
(
Free Report)
Cigna Group NYSE: CI is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.
In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.
See Also
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Group (NYSE:CI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cigna Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cigna Group wasn't on the list.
While Cigna Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.